|
|
| Record Information |
| Record ID |
75 |
| Pubmed ID |
30128502 |
| SNP |
|
| Gene ID |
3558 |
| Protein ID |
P60568 |
| Vaccine Adverse Events |
injectionsite pain; injection-site erythema; and injection-site discomfort, induration, irritation, and cutaneous eruption as well as chills, fatigue, myalgia, and pyrexia. |
| Vaccine |
PVX-410 vaccine |
| Gene Name |
IL2 |
| Official Symbol |
interleukin 2 [Homo sapiens (human)] |
| Aliases |
IL-2, TCGF, lymphokine |
| Other Designations |
interleukin-2; T cell growth factor; aldesleukin; involved in regulation of T-cell clonal expansion |
| Chromosome |
4 |
| Location |
4q27 |
| Annotation |
Chromosome 4 NC_000004.12 (122451470..122456725, complement) |
| MIM |
147680 |
| DNA Sequence |
>NC_000004.12:122451470-122456725 Homo sapiens chromosome 4, GRCh38.p14 Primary Assembly
TTTATATTTATCAAATTTATTAAATAGTTTTACTAACCAATCTACATAGATACTATATTTAACATTCAAC
ATAATAATAAATATTTTGGGATAAATAAGTGAAACCATTTTAGAGCCCCTAGGGCTTACAAAAAGAATCA
TAAAAGATCCATATTTATAGTTTTAAGATTAAGAATAATAGTTACAATAGGTAGCAAACCATACATTCAA
CAATAAATATAAAATTTAAATATTTAAATAAATAGAAGGCCTGATATGTTTTAAGTGGGAAGCACTTAAT
TATCAAGTCAGTGTTGAGATGATGCTTTGACAAAAGGTAATCCATCTGTTCAGAAATTCTACAATGGTTG
CTGTCTCATCAGCATATTCACACATGAATGTTGTTTCAGATCCCTATAAAAGAAAAATGTTAATTTTTTA
AAGTACAGAGTAGTTTACCTTATATACAGTTATTCCCAATTGAAGTCTTATAGGCCTGTTGCCTTTATTT
TCAAGCTTACCAAACATATTAATTATTCACATTTTCTTGAAATGATCAAAATGAATGCCAAAATTACATA
TTTTGTTATGATACCAAATGATAGTAACACAGAAGCTGAGATTTTCCTCATTTGTTAATTCAGTCAATGA
ACACAAAAATTTTTTCCCTAAATTGGGTGCAAATAAAGATTTAAATAAAAATAGATCTAGACAAATATTA
AATGCTGGATGTGAAATAAACTTGATCGCTTTTCCTCTGAATGTACACCTATATTTGTGTAAGTTAAATG
TATGAATTGATATGCACATTATACTTTCTTCTTTTCTAAATCTTGATTAGAGTCTCCTATTTTTCTACTT
AAGTGAATCTCCTTATATTTTCCCCAAAGCAGAACAGAACTACACTAGAGTAAGCTAGGACATGCTTCTG
TTTGGGATAAATTTGTGTGAAGAACATCTTCATAAATACTTACACCTATCCCTACCCCATCATAGTATCA
ATGCAGGTGAATTTGCCAACTTTTAAAAGTTTAAACATTAGAAATTTTGTTCTGTGGACTGGCTTTTTAG
AAATTAGGCTTCTCTGCTGAAAGGAGCTATTTAAACGCTTCCTCTAGTTGATAAGCTAAGGAGGAAATAT
TTTGATATATAGTGAGATTTAAAAGAGAGCTTTTCAAATTTGAAGTGATTCCTACCCTGGGAACAAAAGC
AGGTGAGATAGAGTGTTCCCTTTAAATAAGTATTCTCTTTTAAAAAACTGTTGCAGTGTTCTGTATCCTC
TTAAGCATAATTGTTTAAATATTGTCATATCTTGGGATTTTTTTATTTTAAAAAGTGTTTGGCTTTTGAA
ACACAGTTTTCAGATTTTTGCATGGTTTTGTCTTAAATTTGTATCAAGAGTTAAGAATGAGTTTTCTGAT
GTTAATTATTTTAGAGTAAAACTCTTGCCATAGATAAGGAACTGAATCTGTCAATGTCTAGATGACATTG
ATCTCAATGTATTTTTTTAATTCAACTGAAACAGTCCACTAATAAGTGATTCATTTGGACACAACTGGAG
TTACTTTTAGGAATGTCTTTTACTACTATACTTATGCTGCTTATTTAGGATACCTATTAACTCATGAATT
TTATACCTTAGGAGACGGGATATAAAAAGACAAAAGTGAATCTCTTTTACATCACCTGAGTCCCTTGCAT
ATTTTATGCTTCCTGTGCATTTAAAAATACTTAAGATTCTGAAAGTGGGGATTGCCTCTAAAAAGATTGT
TGTTTGTTTAGTCCACTGGCCATTTTAATGGCTCCAGTTTTTTTTTTTAAGACAAATCTCTTATGGGTAG
TCCTTCCATCAAATGATAAGGAAACACCATTTGAAAAGCCTTTCAGGTAATCAGTATTGGCTATTCCAGT
AAATGATCTGAAGGAATTGAAAAATATATAGTAAAATCTGCCTGCTTTCTGTGAAACTCAACTCAGTACC
TTCTCTCACTCCCAGTTTTGTGTTAATATGAAAGGTGATGGAGTTTGGGATGAGGCTTGTCCATTAGTAG
ATGGTAGGTGCAAACTCAGTAGCTTATACTCCCCAGTTAATCATTTAACATTAGAAATGATTCATGTTCA
CAGTGTACTTAAAATGTAGGCTAATTACATGCATGGGTACTTTACAAATACCAAAAATGTTATGTCACTT
TAAAATGTGGTACTTTTCCCCCTACTTTTTTTTTTTTATTTCCAGGAGAGCAAATAAAGTAATGCCTTAC
CTTTAGTTCCAGAACTATTACGTTGATATTGCTGATTAAGTCCCTGGGTCTTAAGTGAAAGTTTTTGCTT
TGAGCTAAATTTAGCACTTCCTCCAGAGGTTTGAGTTCTTCTTCTAGACACTGAAGATGTTTCAGTTCTG
TGGCCTAGAATAATAATTATCATCAGCTCAGTTTACATAGAGGTCAGAATCAGAAATTAATTTCCAATTT
ATTTTATTTGGAGTAGCAGTATGTAGTTTTTACCATTCTCTCTGTTCTCAATGTCACTGTAAAGATGGAC
CAGTAGAGTTTACATTATAAAACTGGAAAAACTAGGGCTCAAGTACCTATGACTAGCGTTAAGTGATAGT
TGACTCACTGGTTTTAGCTTAATTTGGCTTTGCAAAATGTTAGACTTTCTGCATCTAAATGCCTATTACA
GATGTAGGCTGATTACTTTTCCAATCTGCATAGAAAATCATTAGAACCAGATGAGTTAGAATGTGGAAGC
ATAAAAATCACATTCTATGATTATAATATTTGATAGTCTAAGAGTTAAGAATCACAGAATGTTGAGAGAG
AAGGAACTCTTGGATGCCATCTATCACAATCCCAACATTTTACACTAGGTAACAATAATCATGTAGTAGT
GGCTCTCAATATAGCCTTGAGCAAGACACATTTTTAAATATGTCTTAAATTTTTACTTTTCTACAATCAC
TACATTAAGATGCATTTTAAAAATGTTTGTCCCAGTGAAATAAAAAATTATAATACTTTGGGAGGACTTT
TGGACAGGCCTCTTGATTCTATATTATATATAATATTTCATATTTCTATGGTATATTACAATTTAAAAGA
ATTTTCTCCAAAATAGGCCCATTTACTTCTCACAGTCATCTTTTGAAGTAGGCAGTGAAGTATCATCTCC
ACTTTATAAATAAGCACACTAAATCTCAGAATTTGACCACATAAGTAGGTAGAGCCAGAATTAGATTTCA
TTTCTTTCTCATTATAGCATTAACATAGCATCCTTGGAATCAAATATTTTTATTAGTTTCTAAAATCTTT
TGTAAATGTGCAATGAGGGTTAAATGAACAAATGAATAGAGTTTATCATTACTTTTGGTTTCAAACTTAG
ATTTCCATGAATTCTACCACCCCCTAAATTATGCACATAATCTCATCTTTCTAACACTCTTTAGTGGGAA
AGGTAGGTCAAGACAATACCAATCCCCTGATATGTCCATCTATTGCGCTTTCAATTCACCACTACAAATT
CTACAAATTCGGGTTTAAGTTTTTGGCATGAACAATGTGGAGAAATTTTCTTCAGAAAACAGCATCTAGT
ATCTTTATGTTGCTGGAGTTGCATTATGTGGCTCTGATTAAACTAGAGTAACATCTGTAAGCTGTCTCCT
TTACATCTTTCAGAAGGGTAGTTAGAAGCAGATTTCTCTTGAATTAATAGAATTTGAGTCAATGGGATTG
CATCTGTGTCCCCTTAAATCCTATTATTTTCTGGGCTTGGATTCACCCTGGCACAAGCTCTTTCTGGCAC
CAGATTTTGTTCATTCTCTCTTAACTGGCACAGCTACTAGGTAGCTTTACACACCTAATGTAGCCTAGGA
GCTTGGATGATTATGCTTATGCTCTATCTGAATCCAAAAACAACCTAATGAAGCTTTTAATCTTGGAAAA
TAAGTCATATAGCATTATAAATCTCAAGTTCTATTGGTAAAAAGATAAAGTCCAAAATTTTACTTTGTAT
TTCTCAGTGAAAATTTTATCTTTAATACTACTAATAATAGCTAATGCTTGTATGGTATTTACCTTATGCC
AGACACGGTTCTGAGTGCTTTACATTTACTTACTAATTCTCACAAAGCCATATTAAGTATATACAGTTAT
TCATTTAAGTAGACATGAAACTGAATCACAAACAGAGTAGGTAATTTGCCAAAGATCATGAAAGCTAGGA
CATGGCAGAGCTGAGATTTCACTTCAGATATCTGGCCCCAGACTCTGTGCTATTAGTGTTATGCTGCCTC
TCACTTAGAAACCTTTCCTAAAACAAGAAAAGATTTTTAAAAGTGGGCTCCTTGGAAATAGATTTTGGTA
TTTTACATACTAAAATGACATAATCAAATATTTTAGAGTTTTACATTTTTAAATGAAACCATAAATGAAC
ATTTTTGTTTAGAATTGTCTTATCGATAAAGTGAGAATATTATTTTTATGTTTTCTTCCCACCCCCACCA
ACACACAAATATATATTAAAAATATAGGTAAAACTGTTTTAATAGAGGCTTCATTATCAAACTTGGGTTT
TCAAAAAAACAAATTAAAGTTACTCTTTACCTCAGATGAGCTGCTATTAGTCCCATCTGTGCAAATTTTC
ATATTACTTTGAATTTTATTAAAACAGAAATTGAACATAAAATATTGTACTTACCTTCTTGGGCATGTAA
AACTTAAATGTGAGCATCCTGGTGAGTTTGGGATTCTTGTAATTCTAAGAAAGTATAATGCATTGTTATT
AAGAAATGATCTCCAGCTAGATTACTAAATGTAATAATTTTAGTAAGAAAGGAAATATACTTACATTAAT
TCCATTCAAAATCATCTGTAAATCCAGCAGTAAATGCTCCAGTTGTAGCTGTGTTTTCTTTGTAGAACTT
GAAGTAGGTGCACTGTTTGTGACAAGTGCAAGACTTAGTGCAATGCAAGACAGGAGTTGCATCCTGTACA
TTGTGGCAGGAGTTGAGGTTACTGTGAGTAGTGATTAAAGAGAGTGATAGGGAACTCTTGAACAAGAGAT
GCAATTTATACTGTTAATTCTGGAAAAATATTATGGGGGTGTCAAAATGTTTTACATATTACACATATTT
TCAAAGACTTTACCTGTCTGAAAAAACATTACCTTCATTTTTCCTCTTCTGATGACTCTTTGGAATTTCT
TTAAACCCCCAAAGACTGACTGAATGGATGTAGGTGAAATCCCTCTTTGTTACATTAGCCCACACTTAGG
TGATAG
|
| Protein Name |
IL2_HUMAN |
| Length |
153 |
| Moltype |
AA |
| Topology |
linear |
| Division |
PRI |
| Update Date |
12-OCT-2022 |
| Create Date |
21-JUL-1986 |
| Definition |
RecName: Full=Interleukin-2; Short=IL-2; AltName: Full=T-cell growth factor; Short=TCGF; AltName: INN=Aldesleukin; Flags: Precursor |
| Primary Accession |
P60568 |
| Accession Version |
P60568.1 |
| Other SeqIDs |
sp|P60568.1|IL2_HUMAN,gi|45593462 |
| Organism |
Homo sapiens |
| Taxonomy |
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo |
| Comment |
On or before Mar 15, 2005 this sequence version replaced gi:69701, gi:124325.; [FUNCTION] Cytokine produced by activated CD4-positive helper T-cells and to a lesser extend activated CD8-positive T-cells and natural killer (NK) cells that plays pivotal roles in the immune response and tolerance (PubMed:6438535). Binds to a receptor complex composed of either the high-affinity trimeric IL-2R (IL2RA/CD25, IL2RB/CD122 and IL2RG/CD132) or the low-affinity dimeric IL-2R (IL2RB and IL2RG) (PubMed:16293754, PubMed:16477002). Interaction with the receptor leads to oligomerization and conformation changes in the IL-2R subunits resulting in downstream signaling starting with phosphorylation of JAK1 and JAK3 (PubMed:7973659). In turn, JAK1 and JAK3 phosphorylate the receptor to form a docking site leading to the phosphorylation of several substrates including STAT5 (PubMed:8580378). This process leads to activation of several pathways including STAT, phosphoinositide-3-kinase/PI3K and mitogen-activated protein kinase/MAPK pathways (PubMed:25142963). Functions as a T-cell growth factor and can increase NK-cell cytolytic activity as well (PubMed:6608729). Promotes strong proliferation of activated B-cells and subsequently immunoglobulin production (PubMed:6438535). Plays a pivotal role in regulating the adaptive immune system by controlling the survival and proliferation of regulatory T-cells, which are required for the maintenance of immune tolerance. Moreover, participates in the differentiation and homeostasis of effector T-cell subsets, including Th1, Th2, Th17 as well as memory CD8-positive T-cells. {ECO:0000269|PubMed:16293754, ECO:0000269|PubMed:16477002, ECO:0000269|PubMed:25142963, ECO:0000269|PubMed:6438535, ECO:0000269|PubMed:6608729, ECO:0000269|PubMed:7973659, ECO:0000269|PubMed:8580378}.; [INTERACTION] P60568; P01589: IL2RA; NbExp=3; IntAct=EBI-12508717, EBI-8614302; P60568; P14784: IL2RB; NbExp=5; IntAct=EBI-12508717, EBI-2866779.; [SUBCELLULAR LOCATION] Secreted.; [DISEASE] Note=A chromosomal aberration involving IL2 is found in a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation t(4;16)(q26;p13) with involves TNFRSF17. {ECO:0000269|PubMed:1396583}.; [PHARMACEUTICAL] Available under the name Proleukin (Chiron). Used in patients with renal cell carcinoma or metastatic melanoma.; [SIMILARITY] Belongs to the IL-2 family. {ECO:0000305}.; [SEQUENCE CAUTION] Sequence=AAA59140.1; Type=Erroneous initiation; Evidence={ECO:0000305}.; [WEB RESOURCE] Name=Wikipedia; Note=Interleukin-2 entry; URL='https://en.wikipedia.org/wiki/Interleukin_2'.; [WEB RESOURCE] Name=SeattleSNPs; URL='http://pga.gs.washington.edu/data/il2/'. |
| Source Db |
UniProtKB: locus IL2_HUMAN, accession P60568;; class: standard.; extra accessions:P01585; created: Jul 21, 1986.; sequence updated: Jul 21, 1986.; annotation updated: Oct 12, 2022.; xrefs: X00695.1, CAA25292.1, V00564.1, CAA23827.1, X01586.1, CAA25742.1, J00264.1, AAD48509.1, K02056.1, AAA98792.1, S77834.1, AAD14263.2, S82692.1, AAB46883.1, AF359939.1, AAK26665.1, BC066255.1, AAH66255.1, BC066257.1, AAH66257.1, BC070338.1, AAH70338.1, M33199.1, AAA59139.1, M13879.1, AAA59141.1, M22005.1, AAA59140.1, ICHU2, NP_000577.2, 1IRL_A, 1M47_A, 1M48_A, 1M48_B, 1M49_A, 1M49_B, 1M4A_A, 1M4B_A, 1M4C_A, 1M4C_B, 1NBP_A, 1PW6_A, 1PW6_B, 1PY2_A, 1PY2_B, 1PY2_C, 1PY2_D, 1QVN_A, 1QVN_B, 1QVN_C, 1QVN_D, 1Z92_A, 2B5I_A, 2ERJ_D, 2ERJ_H, 3INK_C, 3INK_D, 3QAZ_A, 3QAZ_D, 3QAZ_G, 3QAZ_J, 3QAZ_M, 3QAZ_P, 3QAZ_S, 3QAZ_V, 3QAZ_Y, 3QAZ_BB, 3QAZ_EE, 3QAZ_HH, 3QB1_A, 3QB1_B, 3QB1_C, 3QB1_D, 3QB1_E, 3QB1_F, 3QB1_G, 3QB1_H, 4NEJ_A, 4NEM_A, 5LQB_A, 5M5E_D, 5UTZ_A, 5UTZ_D, 5UTZ_E, 5UTZ_I, 6LX3_A, 6LX3_B, 6LX3_C, 6LX3_D, 6LXW_A, 6LXW_B, 6LXW_C, 6LXW_D, 6VWU_A, 6YE3_C, 6YE3_F, 6YE3_I, 7DR4_G, 7DR4_I, 7DR4_J, 7DR4_K, 7M2G_A, 7RA9_A, 7RAA_A, 7RAA_B, 7RAA_C, 7RAA_D; xrefs (non-sequence databases): CCDS:CCDS3726.1, PDBsum:1IRL, PDBsum:1M47, PDBsum:1M48, PDBsum:1M49, PDBsum:1M4A, PDBsum:1M4B, PDBsum:1M4C, PDBsum:1NBP, PDBsum:1PW6, PDBsum:1PY2, PDBsum:1QVN, PDBsum:1Z92, PDBsum:2B5I, PDBsum:2ERJ, PDBsum:3INK, PDBsum:3QAZ, PDBsum:3QB1, PDBsum:4NEJ, PDBsum:4NEM, PDBsum:5LQB, PDBsum:5M5E, PDBsum:5UTZ, PDBsum:6LX3, PDBsum:6LXW, PDBsum:6VWU, PDBsum:6YE3, PDBsum:7DR4, PDBsum:7M2G, PDBsum:7RA9, PDBsum:7RAA, AlphaFoldDB:P60568, SMR:P60568, BioGRID:109773, CORUM:P60568, DIP:DIP-475N, IntAct:P60568, STRING:9606.ENSP00000226730, BindingDB:P60568, ChEMBL:CHEMBL5880, DrugBank:DB03455, DrugBank:DB04278, DrugBank:DB03372, DrugBank:DB01327, DrugBank:DB05304, DrugBank:DB05299, DrugBank:DB03453, DrugBank:DB02581, DrugBank:DB00852, DrugBank:DB03957, DrugBank:DB02555, DrugBank:DB06083, DrugBank:DB06584, DrugCentral:P60568, GlyConnect:225, GlyConnect:297, GlyConnect:298, GlyConnect:299, GlyConnect:300, GlyGen:P60568, iPTMnet:P60568, MetOSite:P60568, PhosphoSitePlus:P60568, BioMuta:IL2, DMDM:45593462, MassIVE:P60568, PaxDb:P60568, PeptideAtlas:P60568, PRIDE:P60568, ABCD:P60568, Antibodypedia:4147, DNASU:3558, Ensembl:ENST00000226730.5, Ensembl:ENSP00000226730.5, Ensembl:ENSG00000109471.5, GeneID:3558, KEGG:hsa:3558, MANE-Select:ENST00000226730.5, CTD:3558, DisGeNET:3558, GeneCards:IL2, HGNC:6001, HPA:ENSG00000109471, MIM:147680, neXtProt:NX_P60568, OpenTargets:ENSG00000109471, PharmGKB:PA195, VEuPathDB:HostDB:ENSG00000109471, eggNOG:ENOG502RVR5, GeneTree:ENSGT00390000003555, HOGENOM:CLU_124210_0_0_1, InParanoid:P60568, OMA:NGVNNYE, OrthoDB:1491449at2759, PhylomeDB:P60568, TreeFam:TF338200, PathwayCommons:P60568, Reactome:R-HSA-5673001, Reactome:R-HSA-8877330, Reactome:R-HSA-9020558, Reactome:R-HSA-912526, SignaLink:P60568, SIGNOR:P60568, BioGRID-ORCS:3558, ChiTaRS:IL2, EvolutionaryTrace:P60568, GeneWiki:Interleukin_2, GenomeRNAi:3558, Pharos:P60568, PRO:PR:P60568, Proteomes:UP000005640, RNAct:P60568, Bgee:ENSG00000109471, ExpressionAtlas:P60568, Genevisible:P60568, GO:0005576, GO:0005615, GO:0030246, GO:0005125, GO:0043208, GO:0008083, GO:0005134, GO:0031851, GO:0019209, GO:0050798, GO:0002250, GO:0007155, GO:0007267, GO:0097192, GO:0006955, GO:0002366, GO:0030101, GO:0043066, GO:0002903, GO:0045822, GO:0050728, GO:0050672, GO:0001933, GO:2000320, GO:0042104, GO:0030890, GO:0030307, GO:0008284, GO:0007204, GO:0060999, GO:0002639, GO:0050729, GO:0032729, GO:0032740, GO:0048304, GO:1900100, GO:0045591, GO:0034105, GO:0045944, GO:0042531, GO:0007205, GO:2000561, GO:0046013, GO:0045471, GO:0030217, GO:0006366, GO:0007260, Gene3D:1.20.1250.10, InterPro:IPR009079, InterPro:IPR000779, InterPro:IPR030477, Pfam:PF00715, PRINTS:PR00265, SMART:SM00189, SUPFAM:SSF47266, PROSITE:PS00424 |
| Sequence |
myrmqllscialslalvtnsaptssstkktqlqlehllldlqmilnginnyknpkltrmltfkfympkkatelkhlqcleeelkpleevlnlaqsknfhlrprdlisninvivlelkgsettfmceyadetativeflnrwitfcqsiistlt |
|
